Proactive Investors - Run By Investors For Investors

Aimmune Therapeutics shares bolstered while DBV Technologies' plunges on peanut allergy treatment trial findings

Aimmune Therapeutics shares bolstered while DBV Technologies' plunges on peanut allergy treatment trial findings
Aimmune Therapeutics shares bolstered while DBV Technologies' plunges on peanut allergy treatment trial findings
Not everyone can tolerate peanuts out there

Shares in Aimmune Therapeutics (NASDAQ:AIMT) raced up nearly 30% in New York on Monday in response to the announcement from DBV Technologies' (NASDAQ:DBVT) over its peanut allergy treatment.

Meanwhile, shares in the latter plunged over 46% to US$26.21 to be the worst performer on Nasdaq on Monday. Aimmune Therapeutics on the other hand raced up to US$33.23 each.

Viaskin Peanut,  the DBV treatment, reportedly failed to demonstrate sufficient efficacy in a pivotal phase III trial.

The trial was evaluating the safety and efficacy of Viaskin Peanut in children four to 11 years.

Topline results showed a statistically significant response with a favorable tolerability profile, with 35.3% of patients responding to Viaskin Peanut 250 µg after 12 months of treatment as compared to 13.6% of patients in the placebo arm.

However, the primary endpoint did not reach the point as had been proposed in the study's Statistical Analysis Plan (SAP) submitted to the US FDA.

Aimmune's lead candidate is an orally administered biologic that desensitizes patients with peanut allergy.

A Phase 3 study, PALISADE, is ongoing with an estimated completion date of September 2018.

View full PROAC profile View Profile

Proactiveinvestors Timeline

Related Articles

ipad
September 19 2018
“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients”
Lego ball
September 14 2018
The company's latest push is a joint venture agreement with US-based entertainment firm Three Six Zero, which has steered the careers of pop stars such as Calvin Harris
Throne of Glass
October 23 2018
Rowling, Rowling, Rowling ... keep those titles rolling. Mind you, it's not all about Ms Rowling; Sarah J Maas title revenues grew 47% in the first half of the financial year and dieters are gorging on Tom Kerridge's books
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use